BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform

Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...

July 25, 2023 | News

ConcertAI's TeraRecon Expands Relationship with Change Healthcare for Advanced Visualization in Australia

Advanced visualization and AI leader TeraRecon, a ConcertAI company, is excited to announce an expansion of its reseller and service agreement in Aust...

July 24, 2023 | News

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Summary Total revenue up 21% quarter-on-quarter to $120.7M driven by global product sales Positive operating cash flow ($10.8M, an improvemen...

July 20, 2023 | News

Merck and Telix Continue Collaboration for Targeted Radiation Therapy Studies.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Com...

July 19, 2023 | News

Antengene Administers First Patient in US Clinical Study of ATG-017 for Advanced Solid Tumors with Nivolumab Combination

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop...

July 18, 2023 | News

Antengene's XPOVIO® Approved in Hong Kong for Relapsed Multiple Myeloma

XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...

July 17, 2023 | News

Brii Biosciences Expands Hepatitis B Leadership with Comprehensive Portfolio from Prevention to Cure

Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI in Greater China ...

July 06, 2023 | News

FDA Approves Cu-64 SAR-bisPSMA Phase III Trial for Prostate Cancer

FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on&n...

July 05, 2023 | News

Lumos Receives US FDA Clearance for FebriDx®

The clearance allows FebriDx to be marketed in the US for use by healthcare professionals as an aid in the diagnosis of bacterial acute respiratory infecti...

July 04, 2023 | Regulatory

Lymphoma Therapy Approved for Australian Patients with Diffuse Large B-cell Lymphoma

MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration[1] Recent five-year follow-up data from Phase 2 L-MIND investig...

June 28, 2023 | News

INOVIQ's SubB2M/CA15-3 Breast Cancer Test Shows Excellent Clinical Data

INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) The...

June 28, 2023 | News

SK bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza

SK bioscience will collaborate with one of the world’s leading biomedical research institutes, the Peter Doherty Institute for Infection and Immunity...

June 27, 2023 | News

Psylo Partners with Daiichi Sankyo for Non-Hallucinogenic Psychiatric Therapies

Biotech start-up, Psylo, announced that it has entered into a Sponsored Research Agreement with global Japanese pharmaceutical company, Daiichi ...

June 23, 2023 | News

Telix to Present ZIRCON Phase III Kidney Cancer Imaging Data at SNMMI

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...

June 23, 2023 | News

Stay Connected